TG Therapeutics (TGTX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.34 (+1.01%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of TG Therapeutics (TGTX)
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

Key Insights

Critical company metrics and information

  • Share Price

    $33.93

  • Market Cap

    $5.28 Billion

  • Total Outstanding Shares

    155.67 Million Shares

  • Total Employees

    319

  • Dividend

    No dividend

  • IPO Date

    December 14, 1995

  • SIC Description

    Pharmaceutical Preparations

  • Homepage

    https://www.tgtherapeutics.com

Historical Stock Splits

If you bought 1 share of TGTX before April 30, 2012, you'd have 0.02 shares today.
Execution DateSplit Amount
April 30, 20121-for-56.25 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$134.60 Million
Net Cash Flow From Operating Activities, Continuing$-28.09 Million
Net Cash Flow From Investing Activities, Continuing$-61.58 Million
Net Cash Flow From Operating Activities$-28.09 Million
Net Cash Flow From Financing Activities, Continuing$134.60 Million
Net Cash Flow From Investing Activities$-61.58 Million
Net Cash Flow$44.93 Million
Net Cash Flow, Continuing$44.93 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations Before Tax$-13.88 Million
Benefits Costs and Expenses$278.68 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income/Loss From Continuing Operations After Tax$-14.36 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Basic Earnings Per Share$0.10
Selling, General, and Administrative Expenses$146.49 Million
Operating Income/Loss$505000.00
Operating Expenses$234.35 Million
Net Income/Loss Attributable To Parent$-14.36 Million
Revenues$264.79 Million
Diluted Average Shares$162.92 Million
Income Tax Expense/Benefit$479000.00
Net Income/Loss Available To Common Stockholders, Basic$-14.36 Million
Gross Profit$233.85 Million
Net Income/Loss$-14.36 Million
Costs And Expenses$265.30 Million
Basic Average Shares$145.73 Million
Nonoperating Income/Loss$-13.38 Million
Preferred Stock Dividends And Other Adjustments$0.00
Diluted Earnings Per Share$0.10
Cost Of Revenue$30.94 Million
Research and Development$87.87 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Other Current Assets$148.40 Million
Current Assets$574.07 Million
Liabilities$393.86 Million
Equity Attributable To Parent$192.16 Million
Equity$192.16 Million
Equity Attributable To Noncontrolling Interest$0.00
Noncurrent Liabilities$268.74 Million
Assets$586.01 Million
Current Liabilities$125.11 Million
Inventory$84.67 Million
Cash$341.00 Million
Liabilities And Equity$586.01 Million
Noncurrent Assets$11.95 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.